Bluefin Capital Management, LLC Rapt Therapeutics, Inc. Transaction History
Bluefin Capital Management, LLC
- $1.3 Billion
- Q3 2024
A detailed history of Bluefin Capital Management, LLC transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Bluefin Capital Management, LLC holds 120,000 shares of RAPT stock, worth $116,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120,000Holding current value
$116,400% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RAPT
# of Institutions
100Shares Held
134MCall Options Held
41.3KPut Options Held
100-
Medicxi Ventures Management (Jersey) LTD22.4MShares$21.7 Million7.04% of portfolio
-
Orbimed Advisors LLC San Diego, CA13.1MShares$12.7 Million0.5% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA13.1MShares$12.7 Million3.85% of portfolio
-
Foresite Capital Management Vi LLC Larkspur, CA12.5MShares$12.1 Million8.35% of portfolio
-
Rtw Investments, LP New York, NY11.8MShares$11.4 Million0.24% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $28.8M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...